Affirm Ramps Up Lending Firepower With $750M New York Life Deal and Worldpay Distribution as Q1 FY26 Results Arrive Today (Nov. 6)

6 November 2025

November 6, 2025 — Fintech & Payments | BNPL, AFRM, Worldpay, New York Life

Meta description (SEO): Affirm expands its long‑term capital partnership with New York Life and deepens distribution via Worldpay for Platforms—just hours before reporting Q1 FY26 earnings. Here’s what the deals mean for BNPL, merchants, and investors.

Key takeaways

$750 million forward‑flow from New York Life will see the insurer purchase Affirm installment loans through December 2026, providing off‑balance‑sheet funding that can support ~$1.75B in annual loan volume, per the companies. ^[1]
Worldpay for Platforms integration brings Affirm to 1,000+ SaaS platforms that processed $400B+ in payments and 4.6B transactions over the last 12 months—broadening merchant reach across vertical SaaS. ^[2]
Earnings today (Nov. 6): Affirm is scheduled to report Q1 FY2026 after the bell; Street previews point to roughly $0.10–$0.11 EPS on ~$882–$885M revenue. ^[3]
The moves arrive as Global Payments works to acquire Worldpay, reshaping processor dynamics that could further amplify distribution for embedded BNPL partners like Affirm. ^[4]
They also extend Affirm’s diversified capital stack, following earlier partnerships with Liberty Mutual Investments, PGIM, and Sixth Street. ^[5]

What’s new

Affirm × New York Life, expanded. Affirm said New York Life will buy Affirm’s consumer installment loans on a forward‑flow basis with up to $750M outstanding through Dec. 2026. The structure keeps loans off Affirm’s balance sheet and, by recycling capital, can support about $1.75B in yearly originations—extra capacity headed into peak holiday demand. New York Life has already invested nearly $2B in Affirm collateral via ABS and related structures, underscoring longstanding confidence in Affirm’s credit performance. ^[6]

Affirm × Worldpay, deeper distribution. A separate deal brings Affirm directly into Worldpay for Platforms, enabling platform providers to switch on Affirm at checkout for their merchants. Worldpay says the program spans 1,000+ SaaS platforms and $400B+ in processed volume over the past year; the integration aims to make offering Pay‑in‑4 and monthly installments (30 days up to 60 months; $35–$30,000 carts) as simple as a settings toggle. Quotes from both sides framed it as a friction‑reduction play for platform partners and their merchants. ^[7]

“Bulking up” ahead of earnings. Trade press captured the one‑two punch of a distribution deal plus fresh funding as part of Affirm’s pre‑earnings positioning this week. ^[8]

Why it matters

1) Capital efficiency & risk transfer.
Forward‑flow purchases from an insurer provide predictable liquidity without bloating the balance sheet—vital for BNPL lenders that scale loan volume through varying macro cycles. The New York Life line complements warehouse facilities and securitizations, keeping Affirm’s cost of funds diversified. ^[9]

2) Embedded distribution flywheel.
Worldpay’s platform reach puts Affirm where merchants already operate—inside their vertical SaaS. That can lower integration lift, broaden acceptance, and raise activation rates versus one‑off merchant integrations. ^[10]

3) Processor landscape in flux.
Worldpay’s pending acquisition by Global Payments (expected to close H1 2026) could expand Affirm’s indirect reach if combined merchant networks and tooling accelerate adoption of checkout alternatives like BNPL. ^[11]

By the numbers

$750M: Maximum outstanding balance New York Life will purchase under the forward‑flow through Dec. 2026. ^[12]
~$1.75B/yr: Origination capacity supported by the arrangement, due to loan recycling. ^[13]
1,000+ SaaS platforms | $400B+ volume | 4.6B transactions: Worldpay for Platforms scale over the past year. ^[14]
Earnings consensus: ~$0.10–$0.11 EPS; ~$882–$885M revenue for Q1 FY26 (today). ^[15]

Competitive context: BNPL’s capital arms race

Affirm’s insurer‑ and private‑credit partnerships mirror a broader BNPL trend: institutional buyers funding consumer receivables at scale. In September, PayPal announced a two‑year deal with Blue Owl to sell approximately $7B of U.S. Pay‑in‑4 loans, illustrating the sector’s shift toward committed, off‑balance‑sheet capital. ^[16]

Affirm, for its part, has previously extended its capital base with Liberty Mutual Investments (up to $750M program potential toward $5B) and PGIM Fixed Income ($500M), alongside a $4B investment framework with Sixth Street intended to underpin $20B in loans over three years. Together, these moves broaden funding sources and reduce dependency on any single channel. ^[17]

What to watch in today’s earnings (Nov. 6)

Funding costs & mix: How the New York Life forward‑flow and other facilities shape the blended cost of capital and margins this quarter. ^[18]
GMV & merchant distribution: Early signals from the Worldpay integration and other platform partnerships on activation and conversion uplift. ^[19]
Credit performance: Charge‑offs, delinquencies, and repeat‑use behavior—key to sustaining insurer and private‑credit appetite for Affirm assets. (Preview coverage highlights stable trends to date; details arrive with tonight’s results.) ^[20]
Affirm Card & app engagement: Management has emphasized distribution into direct channels; look for updates following October’s promotional calendar and partner launches ahead of holidays. ^[21]
Outlook into peak season: Guidance on GMV, revenue take rate, and unit economics as holiday shopping accelerates. ^[22]

Analyst & market setup

Previews heading into the print call for EPS around $0.10–$0.11 and revenue around $882–$885M, after a year of sizable beats and improving profitability traction. The after‑market call today will set the tone for the rest of the holiday quarter. ^[23]

Bottom line

On the very day it reports Q1 FY26 results, Affirm is pairing fresh capital with wider pipes. The New York Life expansion strengthens liquidity and capital efficiency; the Worldpay integration broadens distribution. Together, they tilt the company toward faster, lower‑friction growth—while the market waits to see if tonight’s numbers confirm profitability and credit discipline into the holidays. ^[24]

Sources & further reading

Business Wire: Affirm expands long‑term capital partnership with New York Life (details on $750M forward‑flow; ~$1.75B/yr capacity; prior ~$2B invested). ^[25]
Business Wire: Affirm expands partnership with Worldpay for Platforms (1,000+ SaaS, $400B+ volume, product details). ^[26]
American Banker: “Affirm bulks up lending power ahead of earnings” (context on deal timing and strategy). ^[27]
Yahoo Finance roundup on Affirm bulking up lending power (pre‑earnings context). ^[28]
Affirm IR: Earnings timing (Nov. 6, after market). ^[29]
Zacks & MarketBeat: Consensus previews for Q1 FY26. ^[30]
FT / AP: Global Payments to acquire Worldpay (sector backdrop). ^[31]
Reuters / WSJ: Liberty Mutual, PGIM capital partnerships (Affirm’s diversified funding). ^[32]
FT: Sixth Street framework to fund up to $20B in loans over three years. ^[33]
PayPal newsroom: Blue Owl to buy ~$7B Pay‑in‑4 receivables (BNPL capital market context). ^[34]

Disclosure: This article is for information only and is not investment advice.

If you got an AFFIRM LOAN Watch this‼️

Watch this video on YouTube.

References

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

View all

Tesla 2026 Supercycle: 5 Catalysts That Could Ignite TSLA
November 7, 2025, 12:30 AM EST. Tesla's 2026 thesis centers on five bullish catalysts that could lift TSLA despite a transitional period. The piece argues that stocks move on future-forward information, not just current price, and that Tesla's strength lies in disruptive product announcements and software-led upgrades. The five catalysts highlighted include the Robotaxi network powered by FSD and a Cybercab rollout; ongoing cash generation even before new products fully scale; a shift away from the legacy EV business toward high-margin software and services; a broader product and AI roadmap that re-accelerates growth; and potential regulatory, manufacturing, or market catalysts that could force a valuation re-rating. If Musk's vision translates into realized deployments and expanding margins, the stock could experience a large valuation re-rating.
Evolent Health Beats Q3 Revenue, Stock Jumps 14.8% on Mixed Results
November 7, 2025, 12:28 AM EST. Evolent Health (EVH) beat Wall Street on Q3 revenue, generating $479.5 million vs $467.3 million estimates, though year-over-year demand declined 22.8%. The adjusted EPS of $0.05 missed estimates of $0.11 (a 52.5% miss). Adjusted EBITDA came in at $38.96 million, slightly above consensus ($37.67 million). The company guided Q4 revenue of $467 million at the midpoint, below calls for about $472.9 million, and full-year EBITDA guidance of $149 million vs $151.7 million expected. Operating margin improved to 0.2% from -2.6% a year ago; free cash flow margin steady at 1.4%. CEO Seth Blackley cited new contracts (13 this year) and a planned ECP transaction to reduce debt, with a longer-term forecast of $2.5 billion revenue in 2026. Shares rose roughly 14.8%.
Weak US Job News Undercuts the Dollar as Fed Cut Bets Rise; Euro Rises on ECB Divergence
November 7, 2025, 12:20 AM EST. The dollar fell Thursday as the DXY slides about -0.49% after Challenger data showed U.S. job cuts surged 175% y/y in October-the most in 22 years-further boosting bets the Fed will keep cutting rates. The ongoing US government shutdown adds downside risk to growth and reinforces the rate-cut outlook, even as losses were tempered by weaker stocks and a hawkish tilt from policymakers. In the FX space, the EUR/USD rose as the euro drew support from the ECB's looming divergence: the ECB appears closer to finishing its rate-cut cycle while the Fed is expected to deliver additional cuts by 2026. Guindos noted resilience in the euro area, with markets pricing roughly a 70% chance of a -25 bp move at the December FOMC meeting.
Clarus (CLAR) Q3 CY2025: Revenue Beats, EBITDA Surges; Margin Still Negative
November 7, 2025, 12:18 AM EST. Clarus (CLAR) reported Q3 CY2025 results that beat revenue expectations, with revenue of $69.35 million, up 3.3% year over year and above estimates of $66.51 million. The Adjusted EPS was $0.05, in line with consensus, while Adjusted EBITDA jumped to $4.73 million vs $2.70 million expected, expanding the operating margin to -4.4% from -8% a year earlier. Despite the beat, long-term growth appears muted: five-year CAGR around 4.2% and trailing 12-month margins remain negative, suggesting ongoing profitability challenges even as sales stabilize. With buy-side analysts expecting flat revenue over the next 12 months, investors face a delicate balance of a quarterly revenue beat against a tougher growth trajectory and a fragile margin profile.
Tesla to Buy About $2.1B in Energy Storage Batteries From Samsung SDI: What It Means for TSLA Stock
November 7, 2025, 12:15 AM EST. Tesla has reportedly secured a three-year, about $2.1 billion supply deal with Samsung SDI to provide battery cells for its Energy Storage System (ESS) lineup, including Megapack and potentially Powerwall. The deal underlines Tesla's push to scale its growing energy business and tap surging demand for large-scale storage, potentially widening its revenue base beyond autos. For TSLA stock, the news could validate the "more than a car company" thesis and offer some earnings visibility in a volatile market. Yet upside may depend on ESS margins, integration costs, and broader EV demand, so the impact on the share price could be limited if investors remain focused on fundamentals like production, cash flow, and competition.